CD47 and neoplasm: Engineered exosomes, such as GEMINI-Exos armed with anti-CD3, anti-EGFR, PD-1, and OX40L, have demonstrated significant inhibition of triple-negative breast cancer in mice (41), while surface modifications like PEGylation or CD47 overexpression enhance circulation and tumour targeting (26).